

IOWA MEDICAID CLINICAL ADVISORY COMMITTEE ACTIVITY SUMMARY SFY22

OCTOBER 2022



Table of Contents

Medicaid Clinical Advisory Committee Background and Objectives	2
Committee Members	4
Review of Clinical Criteria	6



MEDICAID CLINICAL ADVISORY COMMITTEE BACKGROUND AND OBJECTIVES

The establishment and requirements of the Iowa Medicaid Clinical Advisory Committee (CAC) are contained in House File 841 and the Medicaid CAC was initiated in 2006. The purpose of the Medicaid CAC is to increase the efficiency, quality, and effectiveness of the Iowa Medicaid healthcare system. The CAC provides a process for physicians and other healthcare providers to promote quality care, member safety, and fiscal responsibility through a discussion of Medicaid benefits and healthcare services criteria.

The Medicaid CAC is charged with recommending clinically appropriate healthcare utilization management and coverage decisions for the lowa Medicaid program. This annual report summarizes the recommendations made by the Medicaid CAC and those adopted by rule.

The Medicaid CAC performs:

- Technology and therapeutics review for advanced therapy and new technology.
- Administrative support through its review and recommendations regarding policy issues.
- Criteria review with recommendations for changes.

The Medicaid CAC meetings are subject to the open committee rules in Chapter 21 of the Iowa Administrative Code. All meetings are publicly announced on the DHS website a minimum of 10 days prior to the scheduled date and time. All meeting agendas, minutes, a summary of Medicaid CAC responsibilities, and Medicaid CAC questions and answers are posted on the DHS website.

Appointments are for 3 years, and each member may be reappointed for one additional 3-year term.

The Iowa Medicaid Quality Improvement Organization (QIO) unit is responsible for the administration of the Medicaid CAC. The Iowa Medicaid medical director, Dr. William (Bill) Jagiello, chairs the Medicaid CAC. The chair of the Medicaid CAC may only vote in the situation that the committee has a tie vote.

Else Umbreit, PharmD, is part of the QIO unit and is experienced working in the managed care setting. She applies her knowledge in the review and development of criteria for physician administered medications, as well as with new code reviews.

The Medicaid managed care organizations (MCO) send clinical representation, typically an MCO medical director, to the Medicaid CAC meetings. The MCO medical directors are not voting members of the Medicaid CAC; however, they contribute to clinical criteria discussions to ensure criteria are implemented consistently.

The Medicaid CAC evaluates the clinical aspects of Iowa Medicaid coverage policies and medical management strategies to maximize both quality healthcare and cost effectiveness. The Medicaid CAC provides recommendations in the early stages of policy development and change, through collaboration with the Policy unit, which enhances buy-in from the Medicaid provider network.



COMMITTEE MEMBERS

Clarice Blanchard PA-C, MMS

Clarice Blanchard graduated from Luther College in Decorah, Iowa, with a Bachelor of Arts in Biology and Psychology in 1996. She then received her physician assistant training at St. Louis University in St. Louis, Missouri, graduating in 1999. Clarice has practiced in family medicine and emergency medicine at Madison County Healthcare System in Winterset, Iowa, since 2001.

Dana Danley, MD

Dr. Danley graduated from the University of Iowa College of Medicine, Iowa City, Iowa, in 1998. She completed her post-graduate training in family practice at Broadlawns Medical Center in 2001 and is board-certified in Family Practice. Dr. Danley is an active educator in medical student education as an Adjunct Assistant Family Medicine faculty at Des Moines University and an Adjunct Clinical Associate Professor at the Carver College of Medicine. Dr. Danley also is a faculty member of the Broadlawns Medical Center Family Medicine Residency and has received several awards for teaching. She currently practices at Broadlawns Medical Clinic in Des Moines, Iowa.

Polly Ferguson, MD

Dr. Ferguson graduated from the University of Iowa Carver College of Medicine in Iowa City, Iowa, in 1990. She completed a pediatric residency in 1993, a pediatric rheumatology and immunology fellowship in 1996 and a post-doctoral research fellowship in 2000 at the University of Virginia in Charlottesville, Virginia. Dr. Ferguson joined the faculty at the University of Alabama at Birmingham in 2000 and subsequently took a faculty position at the University of Iowa in 2002 where she remains. She currently is a Professor of Pediatrics and Director of Pediatric Rheumatology, Allergy, and Immunology at the University of Iowa Stead Family Department of Pediatrics.

Alexandra K. Hubbell, DO

Dr. Hubbell graduated from Des Moines University in 2007 and completed her residency at Iowa Lutheran Family Medicine Program in Des Moines, Iowa, in 2013. Dr. Hubbell is the Associate Program Director at the Iowa Lutheran Family Medicine Residency.

Kathleen Lange, MD

Dr. Lange graduated from the University of Iowa College of Medicine in Iowa City, Iowa, in 1992. She completed her residency at Iowa Lutheran Hospital in Des Moines, Iowa, in 1997. She actively participates in several professional affiliations and memberships. Dr. Lange currently practices at Chariton Valley Medical Center in Centerville, Iowa, in family practice.

Stephen R. Mandler, DO

Dr. Mandler is board certified in Adult, Child, and Adolescent Psychiatry. He did his Medical Internship at Oregon Health and Sciences University, and Residency and Fellowship at The Menninger Clinic. He is currently the Chief Medical Officer at Orchard Place. Orchard Place annually serves more than 10,000 children across Iowa from birth to age 22 through a wide variety of mental health services for children and young adults. Previously he served as Regional Medical Officer Psychiatrist, US Department of State, Foreign Service, and worked in Afghanistan, Mexico, and West Africa. He has served on the faculty of Oregon Health Sciences University and Portland State University's Graduate Program of Infant/Toddler Mental Health. Dr. Mandler is an appointed member of the Iowa Council for Early ACCESS.



Dennis Zachary, MD

Dr. Zachary graduated from the Mayo Medical School in Rochester, Minnesota in 1984. He completed his post-graduate training in family practice at North Memorial Branch at the University of Minnesota in 1987. He is board-certified in family practice, geriatric medicine, and sports medicine. He actively participates in several professional affiliations and memberships. He has been the recipient of numerous military honors. Dr. Zachary currently practices at Mercy South Medical Clinic in Des Moines, Iowa, in family practice.

Chitravathi Yerrapareddy, MD

Dr. Reddy graduated from Kurnool Medical College in May 1994. She completed her internship at Government General Hospital in April 1995. She is board-certified in Internal Medicine, Endocrinology, and American Board of Obesity Medicine. She actively participates in several professional affiliations and community services. Dr. Reddy currently practices at UnityPoint Clinic Diabetes & Endocrinology in Cedar Falls, Iowa.

Diana Smith, DNP, ARNP, FNP-C

Diana Smith graduated from Maryville University in St. Louis, Missouri in August 2022. She actively participates in several professional affiliations and memberships and has received several professional certifications. Diana Smith currently practices at Greene County Family Medicine/UnityPoint Clinic in Jefferson, Iowa, and at McCrary Rost Clinic/Stewart Memorial Community Hospital in Gowrie, Iowa and Lake City, Iowa.



REVIEW OF IOWA MEDICAID CLINICAL CRITERIA

A key function of the Medicaid CAC is to provide Iowa Medicaid with an annual review of the criteria utilized for physician-administered drugs and medical review. Using the wide range of expertise represented by the Medicaid CAC members, review of each established and new criteria considers standards of practice, the effect of treatment on quality of life, functional status, and other relevant aspects of the health of Medicaid members.

QIO Services also recruits specialists throughout lowa to review the following specialized criteria annually:

- Bone marrow and/or peripheral blood stem cell transplant,
- Heart transplant,
- Liver transplant,
- Lung transplant,
- Pancreas transplant,
- Orthodontic procedures, and
- Periodontic procedures.

The table on the following pages list the criteria reviewed by the Medicaid CAC during SFY22.

	,
Criteria	Actioned
Abecma (idecabtagene vicleucel)	October 2021
Adakveo (crizanlizumab-tmca)	July 2021
Amondys 45 (casimersen)	April 2022
Artificial Disc Replacement **NEW**	July 2021
Augmentative Communication Systems	April 2022
Autologous Chondrocyte Implantation	April 2022
Back-up ventilators	July 2021
Bariatric Surgery	January 2022
Bavencio (avelumab)	October 2021
Blepharoplasty	April 2022
Bone Marrow/Peripheral Blood Stem Cell Transplant	January 2022
Botulinum Toxins	April 2022
Breyanzi (lisocabtagene maraleucel)	October 2021
Brineura (cerliponase alpha) ARCHIVED	January 2022



CDAC Ceiling Track Lifts and/or Electric Patient Lifts Chromosomal Microarray Analysis Chromosomal Microarray Analysis Chromosomal Microarray Analysis Chromosomal Microarray Analysis Cochlear Implant April 2022 Cochlear Implant Cochlear Implant Repair and Replacement Continuous Glucose Monitoring Crysvita (burosumab-twza) Crysvita (burosumab-twza) Danyelza (naxitamab-gqgk) Cotober 2021 Elaprase (idursulfase) Elaprase (Criteria	Actioned
Lifts Chromosomal Microarray Analysis Chromosomal Microarray Analysis January 2022 CMH LOC Cochlear Implant Cochlear Implant Cochlear Implant Repair and Replacement Continuous Glucose Monitoring Crysvita (burosumab-twza) Crysvita (burosumab-twza) Danyelza (naxitamab-gqgk) Cotober 2021 Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) July 2021 Elaprase (idursulfase) Elaprase (idursulfase) January 2022 Enhertu (fam-trastuzumab deruxtecannxki) April 2022 Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) April 2022 Fasenra (benralizumab) July 2021 Fecal Microbiota Transplantation January 2022 Gait Trainer/ Stander April 2022 Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) April 2022 Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	CDAC	April 2022
CMH LOC Cochlear Implant Cochlear Implant Cochlear Implant Repair and Replacement Continuous Glucose Monitoring Crysvita (burosumab-twza) CT Colonography January 2022 Danyelza (naxitamab-gqgk) Ctober 2021 Elaprase (idursulfase) Elaprase (idursulfase) Cottober 2021 Elaprase (idursulfase) Cottober 2021 Elaprase (idursulfase) Cottober 2021 Elaprase (idursulfase) April 2022 Enhertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fecal Microbiota Transplantation January 2022 Gait Trainer/ Stander April 2022 Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	3	October 2021
Cochlear Implant Cochlear Implant Repair and Replacement Continuous Glucose Monitoring Crysvita (burosumab-twza) Cotober 2021 CT Colonography January 2022 Danyelza (naxitamab-gqgk) Cotober 2021 Elaprase (idursulfase) Elaprase (idursulfase) Cotober 2021 Elaprase (idursulfase) Cotober 2021 Elaprase (idursulfase) Cotober 2021 Elaprase (idursulfase) April 2022 Enhertu (fam-trastuzumab deruxtecannxki) April 2022 Enteral Products and Supplies Invironmental Modification and Adaptive Devices Exondys 51 (eteplirsen) April 2022 Fasenra (benralizumab) July 2021 Fecal Microbiota Transplantation January 2022 Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) April 2022 January 2022 April 2022 April 2022 January 2022 January 2022 January 2022 January 2022 January 2022 January 2022	Chromosomal Microarray Analysis	January 2022
Cochlear ImplanT Repair and Replacement Continuous Glucose Monitoring Crysvita (burosumab-twza) CT Colonography Danyelza (naxitamab-gqgk) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Enertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 July 2021 July 2021 July 2021 January 2022 January 2022 January 2022	CMH LOC	July 2021
Replacement Continuous Glucose Monitoring Crysvita (burosumab-twza) CT Colonography Danyelza (naxitamab-gqgk) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Enhertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) July 2021 Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 July 2021	Cochlear Implant	April 2022
Crysvita (burosumab-twza) CT Colonography January 2022 Danyelza (naxitamab-gqgk) Cotober 2021 Elaprase (idursulfase) Elaprase (idursulfase) Cotober 2021 Elaprase (idursulfase) Cotober 2021 Elaprase (idursulfase) Dotober 2021 Elaprase (idursulfase) Elaprase (idursulfase) January 2022 Enhertu (fam-trastuzumab deruxtecannxki) Enhertu (fam-trastuzumab deruxtecannxki) April 2022 Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) April 2022 Fasenra (benralizumab) July 2021 Fecal Microbiota Transplantation January 2022 Gait Trainer/ Stander April 2022 Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) April 2022 Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	• •	April 2022
CT Colonography Danyelza (naxitamab-gqgk) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Enhertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Continuous Glucose Monitoring	October 2021
Danyelza (naxitamab-gqgk) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Enhertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 July 2021 July 2021 July 2021 January 2022	Crysvita (burosumab-twza)	July 2021
Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Elaprase (idursulfase) Enhertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 July 2021 July 2021	CT Colonography	January 2022
Elaprase (idursulfase) Elaprase (idursulfase) Enhertu (fam-trastuzumab deruxtecannuki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 Junuary 2022 July 2021 July 2021 July 2021 July 2021	Danyelza (naxitamab-gqgk)	October 2021
Elaprase (idursulfase) Enhertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 January 2022 January 2022 January 2022 January 2022	Elaprase (idursulfase)	July 202 I
Enhertu (fam-trastuzumab deruxtecannxki) Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 April 2022 July 2021 July 2021	Elaprase (idursulfase)	October 2021
Enteral Products and Supplies Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 July 2021	Elaprase (idursulfase)	January 2022
Environmental Modification and Adaptive Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 January 2022	`	April 2022
Devices Exondys 51 (eteplirsen) Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Enteral Products and Supplies	July 2021
Fasenra (benralizumab) Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021 July 2021	•	January 2022
Fecal Microbiota Transplantation Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Exondys 51 (eteplirsen)	April 2022
Gait Trainer/ Stander Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Fasenra (benralizumab)	July 202 I
Gene Expression Profiling for the Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Fecal Microbiota Transplantation	January 2022
Management of Breast Cancer (21-gene RT-PCR Assay (Oncotype DX) Genetic Testing (excludes BRCA) Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Gait Trainer/ Stander	April 2022
Genetic Testing for Hereditary Breast and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Management of Breast Cancer (21-gene	July 2021
and Ovarian Cancer Syndrome (BRCA1/BRCA2) Habilitation Eligibility (Non-Financial) July 2021	Genetic Testing (excludes BRCA)	April 2022
	and Ovarian Cancer Syndrome	January 2022
Heart Transplant January 2022	Habilitation Eligibility (Non-Financial)	July 202 I
	Heart Transplant	January 2022



Criteria	Actioned
High Frequency Chest Wall Oscillators	April 2022
Home and Vehicle Modification	January 2022
ICF/ID LOC	January 2022
Iluvien, Retisert, & Yutiq (fluocinolone acetate intravitreal implant) ARCHIVED	October 2021
Imfinzi (durvalumab)	January 2022
Jelmyto (mitomycin gel)	April 2022
Kadcyla (ado-trastuzumab emtansine)	July 2021
Kadcyla (ado-trastuzumab emtansine)	October 2021
Keytruda (pembrolizumab)	April 2022
Krystexxa (pegloticase)	April 2022
Kymriah (tisagenlecleucel)	January 2022
Kymriah (tisagenlecleucel)	April 2022
Laser Linear Accelerator Based Stereotactic Radiosurgery	July 202 I
Left Ventricular Assist Device **NEW**	July 202 I
Liver Transplant	January 2022
Lung Transplant	January 2022
Lutathera (lutetium Lu 177 dotatate)	January 2022
Luxturna (voretigene neparvovec-rzyl)	April 2022
Mobility Related Device Purchase	January 2022
Myoelectric Prosthesis Upper Extremity	January 2022
Namenda (memantine) for ASD	July 2021
Negative Pressure Wound Therapy	April 2022
Nipple Tattooing	January 2022
Non-Invasive Prenatal Testing for Aneuploidy Using Cell Free DNA	January 2022
Nursing Facility Level of Care	April 2022
Ocrevus (ocrelizumab)	April 2022
Orphan Drugs (Rare Diseases) - added Cablivi (caplacizumab-yhdp), Givlaari (givosiran)	July 2021



Criteria	Actioned
Orphan Drugs (Rare Diseases) – added Brineura (cerliponase alpha)	January 2022
Orthodontic Procedures	October 2021
Padcev (enfortumab vedotin-efjv)	October 2021
Pancreas Transplant	January 2022
Panniculectomy	October 2021
Pediatric SNF Level of Care	January 2022
Percussors	July 2021
Periodontic Procedures	January 2022
Periodontic Procedures	January 2022
Personal Care Services for Children	April 2022
Pneumatic Compression Devices	July 2021
Power Seat Elevation for Power Wheelchairs	January 2022
Power Wheelchair Attendant Controls	January 2022
Pre-vocational Services	January 2022
Private Duty Nursing for Children	April 2022
Psychiatric Medical Institution for Children Level of Care	April 2022
Radicava (edaravone)	April 2022
Reduction Mammoplasty/Mastopexy	July 202 I
ReliZORB **NEW**	January 2022
Risk Reduction Mastectomy	July 2021
Safety Beds	April 2022
Sarclisa (isatuximab-irfc)	July 2021
Septoplasty/ Rhinoplasty	April 2022
Shower/Commode Chair	April 2022
Skilled Level of Care	April 2022
Spinraza (nusinersen)	July 202 I
Spravato (esketamine) Nasal Spray	April 2022
Strollers and Wheelchairs for Safety	July 2021



Criteria	Actioned
Tecartus (brexucabtagene autoleucel)	January 2022
Tepezza (teprotumumab-trbw)	April 2022
Transcranial Magnetic Stimulation	October 2021
Trodelvy (sacituzumab govitecan-hziy)	July 202 I
Tysabri (natalizumab govitecan-hziy)	April 2022
Uplizna (inebilizumab-cdon)	July 2021
Vagus Nerve Stimulator	April 2022
Viltepso (viltolarsen)	July 2021
Viltepso (viltolarsen)	April 2022
Visual Aids and Vision Therapy	October 2021
Vitamin, Mineral, Amino Acid Supplements	April 2022
Vivitrol (extended-release naltrexone injection) ARCHIVED	October 2021
Vyepti (eptinezumab-jjmr)	January 2022
Vyondys 53 (golodirsen)	April 2022
Wearable Automated External Defibrillator	July 202 I
Whole Exome Sequencing	January 2022
Yescarta (axicabtagene ciloleucel)	July 202 I
Zolgensma (onasemnogene abeparvovec- xioi)	July 2021
Zulresso (brexanolone)	October 2021